Longitudinal tracking of triple labeled umbilical cord derived mesenchymal stromal cells in a mouse model of Amyotrophic Lateral Sclerosis

Stem Cell Research

Volumn 15, Issue 1, 2015, Pages 243-253

  Violatto, Martina Bruna ^a   Santangelo, Chiara ^a   Capelli, Chiara ^b   Frapolli, Roberta ^a   Ferrari, Raffaele ^a   Sitia, Leopoldo ^a   Tortarolo, Massimo ^a   Talamini, Laura ^a   Previdi, Sara ^a   Moscatelli, Davide ^c   Salmona, Mario ^a   Introna, Martino ^b   Bendotti, Caterina ^a   Bigini, Paolo ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^c POLITECNICO DI MILANO   (Italy)

Author keywords

Amyotrophic Lateral Sclerosis; Cell tracking; In vivo imaging; Mesenchymal stromal cells; Nanotechnology; Umbilical cord

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; NANOPARTICLE; POLY(METHYL METHACRYLATE);

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRACKING; CHOROID PLEXUS; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; LATERAL BRAIN VENTRICLE; MESENCHYMAL STROMA CELL; MOUSE; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SYNTHESIS; TRANSGENIC MOUSE; UMBILICAL CORD; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; CELL SIZE; CYTOLOGY; DISEASE MODEL; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MESENCHYMAL STEM CELL TRANSPLANTATION; PATHOLOGY; STAINING; TISSUE DISTRIBUTION;

MURINAE; MUS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CELL SIZE; CELL TRACKING; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE, INBRED C57BL; MICE, TRANSGENIC; ORGAN SPECIFICITY; STAINING AND LABELING; TISSUE DISTRIBUTION; UMBILICAL CORD;

EID: 84938584853     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2015.06.010     Document Type: Article

References (57)

1. Al-Chalabi A., Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013, 9:617-628.
2. Bigini P., Veglianese P., Andriolo G., Cova L., Grignaschi G., Caron I., Daleno C., Barbera S., Ottolina A., Calzarossa C., Lazzari L., Mennini T., Bendotti C., Silani V. Intracerebroventricular administration of human umbilical cord blood cells delays disease progression in two murine models of motor neuron degeneration. Rejuvenation Res. 2011, 14:623-639.
3. Bigini P., Diana V., Barbera S., Fumagalli E., Micotti E., Sitia L., Paladini A., Bisighini C., De Grada L., Coloca L., Colombo L., Manca P., Bossolasco P., Malvestiti F., Fiordaliso F., Forloni G., Morbidelli M., Salmona M., Giardino D., Mennini T., Moscatelli D., Silani V., Cova L. Longitudinal tracking of human fetal cells labeled with super paramagnetic iron oxide nanoparticles in the brain of mice with motor neuron disease. PLoS One 2012, 7:e32326.
4. Bigini P., Previdi S., Casarin E., Silvestri D., Violatto M.B., Facchin S., Sitia L., Rosato A., Zuccolotto G., Realdon N., Fiordaliso F., Salmona M., Morpurgo M. In vivo fate of avidin-nucleic acid nanoassemblies as multifunctional diagnostic tools. ACS Nano 2014, 8:175-187.
5. Bjorklund A., Lindvall O. Cell replacement therapies for central nervous system disorders. Nat. Neurosci. 2000, 3:537-544.
6. Bossolasco P., Cova L., Levandis G., Diana V., Cerri S., Lambertenghi Deliliers G., Polli E., Silani V., Blandini F., Armentero M.T. Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease. Int. J. Nanomedicine 2012, 7:435-447.
7. Bull E., Madani S.Y., Sheth R., Seifalian A., Green M., Seifalian A.M. Stem cell tracking using iron oxide nanoparticles. Int. J. Nanomedicine 2014, 9:1641-1653.
8. Calero M., Gutierrez L., Salas G., Luengo Y., Lazaro A., Acedo P., Morales M.P., Miranda R., Villanueva A. Efficient and safe internalization of magnetic iron oxide nanoparticles: two fundamental requirements for biomedical applications. Nanomedicine 2014, 10:733-743.
9. Canzi L., Castellaneta V., Navone S., Nava S., Dossena M., Zucca I., Mennini T., Bigini P., Parati E.A. Human skeletal muscle stem cell antiinflammatory activity ameliorates clinical outcome in amyotrophic lateral sclerosis models. Mol. Med. 2012, 18:401-411.
10. Capelli C., Gotti E., Morigi M., Rota C., Weng L., Dazzi F., Spinelli O., Cazzaniga G., Trezzi R., Gianatti A., Rambaldi A., Golay J., Introna M. Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. Cytotherapy 2011, 13:786-801.
11. Cheah B.C., Vucic S., Krishnan A.V., Kiernan M.C. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem. 2010, 17:1199-1942.
12. Chen R., Ende N. The potential for the use of mononuclear cells from human umbilical cord blood in the treatment of amyotrophic lateral sclerosis in SOD1 mice. J. Med. 2000, 31:21-30.
13. Corti S., Locatelli F., Donadoni C., Guglieri M., Papadimitriou D., Strazzer S., Del Bo R., Comi G.P. Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain 2004, 127:2518-2532.
14. Cova L., Bigini P., Diana V., Sitia L., Ferrari R., Pesce R.M., Khalaf R., Bossolasco P., Ubezio P., Lupi M., Tortarolo M., Colombo L., Giardino D., Silani V., Morbidelli M., Salmona M., Moscatelli D. Biocompatible fluorescent nanoparticles for in vivo stem cell tracking. Nanotechnology 2013, 24:245603.
15. Diana V., Bossolasco P., Moscatelli D., Silani V., Cova L. Dose dependent side effect of superparamagnetic iron oxide nanoparticle labeling on cell motility in two fetal stem cell populations. PLoS One 2013, 8:e78435.
16. Doble A., Kennel P. Animal models of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor. Neuron Disord. 2000, 1:301-312.
17. Duan X., Li Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small 2013, 9:1521-1532.
18. Ferrari R., Lupi M., Falcetta F., Bigini P., Paolella K., Fiordaliso F., Bisighini C., Salmona M., D'Incalci M., Morbidelli M. Integrated multiplatform method for in vitro quantitative assessment of cellular uptake for fluorescent polymer nanoparticles. Nanotechnology 2014, 25:045102.
19. Fischer U.M., Harting M.T., Jimenez F., Monzon-Posadas W.O., Xue H., Savitz S.I., Laine G.A., Cox C.S. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009, 18:683-692.
20. Garbuzova-Davis S., Willing A.E., Zigova T., Saporta S., Justen E.B., Lane J.C., Hudson J.E., Chen N., Davis C.D., Sanberg P.R. Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation. J. Hematother. Stem Cell Res. 2003, 12:255-270.
21. Garbuzova-Davis S., Sanberg C.D., Kuzmin-Nichols N., Willing A.E., Gemma C., Bickford P.C., Miller C., Rossi R., Sanberg P.R. Human umbilical cord blood treatment in a mouse model of ALS: optimization of cell dose. PLoS One 2008, 3:e2494.
22. Garbuzova-Davis S., Rodrigues M.C., Mirtyl S., Turner S., Mitha S., Sodhi J., Suthakaran S., Eve D.J., Sanberg C.D., Kuzmin-Nichols N., Sanberg P.R. Multiple intravenous administrations of human umbilical cord blood cells benefit in a mouse model of ALS. PLoS One 2012, 7:e31254.
23. Gordon P.H. Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis. 2013, 4:295-310.
24. Griffin M.D., Elliman S.J., Cahill E., English K., Ceredig R., Ritter T. Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots?. Stem Cells 2013, 31:2033-2041.
25. Harms M.B., Baloh R.H. Clinical neurogenetics: amyotrophic lateral sclerosis. Neurol. Clin. 2013, 31:929-950.
26. Jokerst J.V., Thangaraj M., Kempen P.J., Sinclair R., Gambhir S.S. Photoacoustic imaging of mesenchymal stem cells in living mice via silica-coated gold nanorods. ACS Nano 2012, 6:5920-5930.
27. Knippenberg S., Thau N., Schwabe K., Dengler R., Schambach A., Hass R., Petri S. Intraspinal injection of human umbilical cord blood-derived cells is neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener. Dis. 2012, 9:107-120.
28. Li L., Jiang W., Luo K., Song H., Lan F., Wu Y., Gu Z. Superparamagnetic iron oxide nanoparticles as MRI contrast agents for non-invasive stem cell labeling and tracking. Theranostics 2013, 3:595-615.
29. Lindvall O., Kokaia Z. Stem cells for the treatment of neurological disorders. Nature 2006, 441:1094-1096.
30. Mahmoudi M., Hofmann H., Rothen-Rutishauser B., Petri-Fink A. Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. Chem. Rev. 2012, 112:2323-2338.
31. Mitrecic D., Nicaise C., Gajovic S., Pochet R. Distribution, differentiation, and survival of intravenously administered neural stem cells in a rat model of amyotrophic lateral sclerosis. Cell Transplant. 2010, 19:537-548.
32. Musaro A. Understanding ALS: new therapeutic approaches. FEBS J. 2013, 280:4315-4322.
33. Nystedt J., Anderson H., Tikkanen J., Pietila M., Hirvonen T., Takalo R., Heiskanen A., Satomaa T., Natunen S., Lehtonen S., Hakkarainen T., Korhonen M., Laitinen S., Valmu L., Lehenkari P. Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. Stem Cells 2013, 31:317-326.
34. Reddy L.H., Arias J.L., Nicolas J., Couvreur P. Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem. Rev. 2012, 112:5818-5878.
35. Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001, 344:1688-1700.
36. Ruster B., Gottig S., Ludwig R.J., Bistrian R., Muller S., Seifried E., Gille J., Henschler R. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108:3938-3944.
37. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J. Control. Release 2010, 145:182-195.
38. Schrepfer S., Deuse T., Reichenspurner H., Fischbein M.P., Robbins R.C., Pelletier M.P. Stem cell transplantation: the lung barrier. Transplant. Proc. 2007, 39:573-576.
39. Shah N.B., Vercellotti G.M., White J.G., Fegan A., Wagner C.R., Bischof J.C. Blood-nanoparticle interactions and in vivo biodistribution: impact of surface PEG and ligand properties. Mol. Pharm. 2012, 9:2146-2155.
40. Silani V., Calzarossa C., Cova L., Ticozzi N. Stem cells in amyotrophic lateral sclerosis: motor neuron protection or replacement?. CNS Neurol. Disord. Drug Targets 2010, 9:314-324.
41. Sitia L., Paolella K., Romano M., Violatto M.B., Ferrari R., Fumagalli S., Colombo L., Bello E., De Simoni M.G., D'Incalci M., Morbidelli M., Erba E., Salmona M., Moscatelli D., Bigini P. An integrated approach for the systematic evaluation of polymeric nanoparticles in healthy and diseased organisms. J. Nanoparticle Res. 2014, 16:1-16.
42. Souayah N., Coakley K.M., Chen R., Ende N., McArdle J.J. Defective neuromuscular transmission in the SOD1 G93A transgenic mouse improves after administration of human umbilical cord blood cells. Stem Cell Rev. 2012, 8:224-228.
43. Srivastava A.K., Bulte J.W. Seeing stem cells at work in vivo. Stem Cell Rev. 2014, 10:127-144.
44. Stagg J., Galipeau J. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr. Mol. Med. 2013, 13:856-867.
45. Sutton E.J., Henning T.D., Pichler B.J., Bremer C., Daldrup-Link H.E. Cell tracking with optical imaging. Eur. Radiol. 2008, 18:2021-2032.
46. Tenuta T., Monopoli M.P., Kim J., Salvati A., Dawson K.A., Sandin P., Lynch I. Elution of labile fluorescent dye from nanoparticles during biological use. PLoS One 2011, 6:e25556.
47. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8:726-736.
48. Uccelli A., Benvenuto F., Laroni A., Giunti D. Neuroprotective features of mesenchymal stem cells. Best Pract. Res. Clin. Haematol. 2011, 24:59-64.
49. Uccelli A., Milanese M., Principato M.C., Morando S., Bonifacino T., Vergani L., Giunti D., Voci A., Carminati E., Giribaldi F., Caponnetto C., Bonanno G. Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. Mol. Med. 2012, 18:794-804.
50. Vaegler M., Maerz J.K., Amend B., da Silva L.A., Mannheim J.G., Fuchs K., Will S., Sievert K.D., Stenzl A., Hart M.L., Aicher W.K. Labelling and tracking of human mesenchymal stromal cells in preclinical studies and large animal models of degenerative diseases. Curr. Stem Cell Res. Ther. 2014, 9:444-450.
51. Viswanathan S., Keating A. Overcoming the challenges of conducting translational research in cell therapy. Front. Med. 2011, 5:333-335.
52. Wang P., Moore A. Molecular imaging of stem cell transplantation for neurodegenerative diseases. Curr. Pharm. Des. 2012, 18:4426-4440.
53. Willing A.E., Garbuzova-Davis S., Sanberg P.R., Saporta S. Routes of stem cell administration in the adult rodent. Methods Mol. Biol. 2008, 438:383-401.
54. Wong F.S., Chan B.P., Lo A.C. Carriers in cell-based therapies for neurological disorders. Int. J. Mol. Sci. 2014, 15:10669-10723.
55. Zanotti L., Sarukhan A., Dander E., Castor M., Cibella J., Soldani C., Trovato A.E., Ploia C., Luca G., Calvitti M., Mancuso F., Arato I., Golemac M., Jonjic N., Biondi A., Calafiore R., Locati M., D'Amico G., Viola A. Encapsulated mesenchymal stem cells for in vivo immunomodulation. Leukemia 2013, 27:500-503.
56. Zhao C.P., Zhang C., Zhou S.N., Xie Y.M., Wang Y.H., Huang H., Shang Y.C., Li W.Y., Zhou C., Yu M.J., Feng S.W. Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice. Cytotherapy 2007, 9:414-426.
57. Zoja C., Garcia P.B., Rota C., Conti S., Gagliardini E., Corna D., Zanchi C., Bigini P., Benigni A., Remuzzi G., Morigi M. Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. Am. J. Physiol. Ren. Physiol. 2012, 303:F1370-F1381.